Ostrum Asset Management Takes Position in TESARO Inc (TSRO)

Ostrum Asset Management acquired a new stake in TESARO Inc (NASDAQ:TSRO) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,949 shares of the biopharmaceutical company’s stock, valued at approximately $111,000.

Several other hedge funds also recently modified their holdings of the company. SG Americas Securities LLC purchased a new position in shares of TESARO in the 1st quarter valued at about $110,000. American International Group Inc. increased its stake in shares of TESARO by 138.8% in the 1st quarter. American International Group Inc. now owns 2,099 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 1,220 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new position in shares of TESARO in the 1st quarter valued at about $220,000. Stifel Financial Corp purchased a new position in shares of TESARO in the 1st quarter valued at about $241,000. Finally, Two Sigma Securities LLC purchased a new position in shares of TESARO in the 4th quarter valued at about $255,000.

Several equities analysts recently weighed in on TSRO shares. Barclays cut their price target on TESARO from $135.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 28th. Credit Suisse Group cut their price objective on TESARO from $141.00 to $128.00 and set an “outperform” rating for the company in a research note on Friday, May 4th. Robert W. Baird reiterated a “hold” rating on shares of TESARO in a research note on Tuesday, April 24th. Lake Street Capital reiterated a “buy” rating and set a $80.00 price objective (down from $120.00) on shares of TESARO in a research note on Monday, May 7th. Finally, BidaskClub upgraded TESARO from a “sell” rating to a “hold” rating in a research note on Tuesday, March 13th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and fifteen have given a buy rating to the company. TESARO currently has a consensus rating of “Buy” and a consensus target price of $112.57.



In other news, Director Lawrence M. Alleva sold 7,142 shares of the business’s stock in a transaction that occurred on Tuesday, June 12th. The stock was sold at an average price of $43.11, for a total transaction of $307,891.62. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 33.70% of the company’s stock.

Shares of TESARO stock traded down $0.32 on Monday, hitting $39.45. 4,982 shares of the company were exchanged, compared to its average volume of 2,129,197. The stock has a market cap of $2.18 billion, a P/E ratio of -4.34 and a beta of 1.23. TESARO Inc has a 1-year low of $39.45 and a 1-year high of $153.98. The company has a debt-to-equity ratio of 3.74, a current ratio of 4.02 and a quick ratio of 3.56.

TESARO (NASDAQ:TSRO) last issued its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($2.98) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.56) by ($0.42). The company had revenue of $49.74 million for the quarter, compared to analyst estimates of $56.34 million. TESARO had a negative return on equity of 177.92% and a negative net margin of 193.42%. The company’s revenue for the quarter was up 1520.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($2.55) earnings per share. research analysts expect that TESARO Inc will post -10.08 EPS for the current fiscal year.

TESARO Profile

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO Inc (NASDAQ:TSRO).

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply